An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Phase 2 Terminated 160 enrolled Genentech, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This Phase II, multicenter, open-label extension (OLE) study will evaluate the long-term safety and efficacy of GDC-0853 in participants with systemic lupus erythematosus (SLE) who have completed Study GA30044 (NCT02908100) up to 48 weeks.

Timeline

Start: 2018-01-09
Primary completion: 2019-11-20
Completion: 2019-11-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fenebrutinib	Small molecule	200 mg	Oral

An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Summary

Timeline

Drugs

Indications